26 Aug 2020 --- Evolva’s half-year 2020 results reveal a record order intake of CHF6.2 million (US$6.8 million) driven by the Health Ingredients sector. However, only CHF3.8 million (US$4.2 million) could be realized due to COVID-19-related delays at contract manufacturing organizations (CMOs). The company has also faced other pandemic headwinds, flagging stagnating customer demand in Flavors and Fragrances (F&F). Overall, the company anticipates cash outflows to be above the 2019 level, part of which will be related to a scale-up of production capacities and a major product launch.
